Mirum Pharmaceuticals Gears Up for J.P. Morgan Healthcare Conference Presentation on Rare Disease Therapies

Mirum Pharmaceuticals Prepares for Key Presentation at J.P. Morgan Healthcare Conference

Mirum Pharmaceuticals, Inc., a focused biopharmaceutical company, gears up to present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on January 15, 2025. This event is pivotal for Mirum as it showcases the company’s advancements in developing therapies for rare and orphan diseases. The presentation will start at 9:45 a.m. PT and will be available via live webcast, with a replay accessible for 30 days. Mirum’s commitment to addressing unmet medical needs in rare diseases positions it as a significant player in the biopharmaceutical landscape.

At the forefront of Mirum's therapeutic offerings are three approved medications: LIVMARLI® (maralixibat), CHOLBAM® (cholic acid), and CHENODAL® (chenodiol). LIVMARLI, an IBAT inhibitor, is specifically designed to treat cholestatic pruritus in patients suffering from Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC). It is approved for use in children as young as three months in the U.S. and two months in Europe, showcasing the company's dedication to pediatric care. Furthermore, Mirum is launching the Phase 3 EXPAND study to evaluate potential label expansion for LIVMARLI, reflecting its proactive approach to enhancing treatment options for patients.

In addition to its approved products, Mirum is advancing a robust late-stage pipeline. The company is currently investigating Volixibat, which is undergoing evaluation in two registrational studies targeting primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC). Notably, Volixibat has received Breakthrough Therapy Designation for treating cholestatic pruritus in patients with PBC, underscoring its potential impact on patient care. Positive topline results from the Phase 3 RESTORE study for CTX were also reported in 2023, leading to the submission of a new drug application to the FDA for chenodiol approval. Furthermore, Mirum has plans for a Phase 2 study for MRM-3379, a PDE4D inhibitor aimed at treating Fragile X syndrome, highlighting its commitment to innovative research in rare diseases.

As Mirum Pharmaceuticals prepares for its upcoming presentation, the company continues to make strides in expanding its therapeutic offerings, ensuring that patients with rare and orphan diseases have access to much-needed treatments. The focus on both approved medications and investigational therapies positions Mirum as a leader in the biopharmaceutical industry, dedicated to improving the lives of patients with limited options.